https://www.selleckchem.com/products/pd123319.html
8% (95% CI 84.6% to 88.7%) in individuals 50 to 79-years-old compared to 80.3% (95% CI 75.1% to 84.3%) in individuals ages 80 and older. In patients with a history of live zoster vaccine within 5 years of study inclusion, vaccine effectiveness was 84.8% (95% CI 75.3% to 90.7%). Recombinant zoster vaccine effectiveness against herpes zoster was high in a real-world setting. Given the low vaccine coverage and high effectiveness, a major public health effort is needed to identify and address barriers to vaccination and increase immunizati
Like
Comment
Share
